Cargando…

Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study

BACKGROUND: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels...

Descripción completa

Detalles Bibliográficos
Autores principales: St. Peter, Wendy L, Yusuf, Akeem A, Do, Thy, Lowe, Kimberly A, Liu, Jiannong, Nieman, Kimberly M, Bradbury, Brian D, Collins, Allan J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383071/
https://www.ncbi.nlm.nih.gov/pubmed/25886282
http://dx.doi.org/10.1186/s12882-015-0030-8
_version_ 1782364674338062336
author St. Peter, Wendy L
Yusuf, Akeem A
Do, Thy
Lowe, Kimberly A
Liu, Jiannong
Nieman, Kimberly M
Bradbury, Brian D
Collins, Allan J
author_facet St. Peter, Wendy L
Yusuf, Akeem A
Do, Thy
Lowe, Kimberly A
Liu, Jiannong
Nieman, Kimberly M
Bradbury, Brian D
Collins, Allan J
author_sort St. Peter, Wendy L
collection PubMed
description BACKGROUND: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. METHODS: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for ≥ 40 days. We grouped patients into quartiles of PTH change after first cinacalcet prescription. We used Cox proportional hazard modeling to evaluate associations between short-term PTH change and time to first composite event (hospitalization for cardiovascular events or mortality) within 1 year. Overall models and models stratified by baseline PTH levels were adjusted for several patient-related factors. RESULTS: For 2485 of 3467 included patients (72%), PTH levels decreased after first cinacalcet prescription; for 982 (28%), levels increased or were unchanged. Several characteristics differed between PTH change groups, including age and mineral-and-bone-disorder laboratory values. In adjusted models, we did not identify an association between greater short-term PTH reduction and lower composite event rates within 1 year, overall or in models stratified by baseline PTH levels. CONCLUSIONS: Short-term change in PTH levels after first cinacalcet prescription does not appear to be a useful surrogate for longer-term improvements in cardiovascular or survival risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0030-8) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4383071
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-43830712015-04-03 Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study St. Peter, Wendy L Yusuf, Akeem A Do, Thy Lowe, Kimberly A Liu, Jiannong Nieman, Kimberly M Bradbury, Brian D Collins, Allan J BMC Nephrol Research Article BACKGROUND: Cinacalcet reduces parathyroid hormone (PTH) levels in patients receiving hemodialysis, but no non-experimental studies have evaluated the association between changes in PTH levels following cinacalcet initiation and clinical outcomes. We assessed whether short-term change in PTH levels after first cinacalcet prescription could serve as a surrogate marker for improvements in longer-term clinical outcomes. METHODS: United States Renal Data System data were linked with data from a large dialysis organization. We created a point prevalent cohort of adult hemodialysis patients with Medicare as primary payer who initiated cinacalcet November 1, 2004-February 1, 2007, and were on cinacalcet for ≥ 40 days. We grouped patients into quartiles of PTH change after first cinacalcet prescription. We used Cox proportional hazard modeling to evaluate associations between short-term PTH change and time to first composite event (hospitalization for cardiovascular events or mortality) within 1 year. Overall models and models stratified by baseline PTH levels were adjusted for several patient-related factors. RESULTS: For 2485 of 3467 included patients (72%), PTH levels decreased after first cinacalcet prescription; for 982 (28%), levels increased or were unchanged. Several characteristics differed between PTH change groups, including age and mineral-and-bone-disorder laboratory values. In adjusted models, we did not identify an association between greater short-term PTH reduction and lower composite event rates within 1 year, overall or in models stratified by baseline PTH levels. CONCLUSIONS: Short-term change in PTH levels after first cinacalcet prescription does not appear to be a useful surrogate for longer-term improvements in cardiovascular or survival risk. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12882-015-0030-8) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-31 /pmc/articles/PMC4383071/ /pubmed/25886282 http://dx.doi.org/10.1186/s12882-015-0030-8 Text en © St. Peter et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
St. Peter, Wendy L
Yusuf, Akeem A
Do, Thy
Lowe, Kimberly A
Liu, Jiannong
Nieman, Kimberly M
Bradbury, Brian D
Collins, Allan J
Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title_full Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title_fullStr Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title_full_unstemmed Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title_short Parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
title_sort parathyroid hormone change after cinacalcet initiation and one-year clinical outcome risk: a retrospective cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383071/
https://www.ncbi.nlm.nih.gov/pubmed/25886282
http://dx.doi.org/10.1186/s12882-015-0030-8
work_keys_str_mv AT stpeterwendyl parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT yusufakeema parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT dothy parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT lowekimberlya parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT liujiannong parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT niemankimberlym parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT bradburybriand parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy
AT collinsallanj parathyroidhormonechangeaftercinacalcetinitiationandoneyearclinicaloutcomeriskaretrospectivecohortstudy